Adverse kidney effects of epidermal growth factor receptor inhibitors.

about

Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides.

P2860

Q42371674-22405D14-E958-4214-852C-80E049BF50EB Q47997273-4F594DF0-B9E6-4BF0-B15D-87E52F76C863

P2860

Adverse kidney effects of epidermal growth factor receptor inhibitors.

Item

http://www.wikidata.org/entity/Q53402902

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Adverse kidney effects of epidermal growth factor receptor inhibitors.

@en

Adverse kidney effects of epidermal growth factor receptor inhibitors.

@nl

type

Item

label

Adverse kidney effects of epidermal growth factor receptor inhibitors.

@en

Adverse kidney effects of epidermal growth factor receptor inhibitors.

@nl

prefLabel

Adverse kidney effects of epidermal growth factor receptor inhibitors.

@en

Adverse kidney effects of epidermal growth factor receptor inhibitors.

@nl

P1476

Adverse kidney effects of epidermal growth factor receptor inhibitors.

@en

P2093

Hassan Izzedine

http://www.w3.org/2001/XMLSchema#string

Mark A Perazella

http://www.w3.org/2001/XMLSchema#string

P2860

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Erlotinib in previously treated non-small-cell lung cancer

P304

1089-1097

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFW467

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28339780

http://www.w3.org/2001/XMLSchema#string

Adverse kidney effects of epidermal growth factor receptor inhibitors.

about

P2860

P2860

Adverse kidney effects of epidermal growth factor receptor inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698